Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.David Andorsky, Jeff P. Sharman, Mitul Gandhi et al.|Journal of Clinical Oncology|2024Cited by 2
ABCL-1224: Updated Results From EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)Rakhee Vaidya, David Andorsky, Farrukh T. Awan et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1